Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeAT Glio: Neoadjuvant Ipilimumab in Newly Diagnosed Glioblastoma
NCT05074992Phase 2Terminated
- Sponsor
- University College London
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in glioblastoma (GBM), sponsored by University College London. Started Aug 2022; status: terminated.
02
Drugs
ipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05074992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074992.